LONDON, March 21, 2014 /PRNewswire/ --
On Thursday, March 20, 2014, the
NASDAQ Composite ended at 4,319.29, up 0.27%, the Dow Jones
Industrial Average gained 0.67% to reach 16,331.05, and the S&P
500 closed at 1,872.01, up 0.60%. The gains were broad based as
nine of ten sectors finished higher. The S&P 500 Health Care
Sector Index finished the day 0.02% lower at 686.29, whereas, the
index has advanced 0.77% in the last one month. Investor-Edge has
initiated coverage on the following equities: IntelliPharmaCeutics
International Inc. (NASDAQ: IPCI), Delcath Systems Inc. (NASDAQ:
DCTH), Valeant Pharmaceuticals International Inc. (NYSE: VRX) and
Alkermes PLC (NASDAQ: ALKS). Free technical research on IPCI, DCTH,
VRX and ALKS can be downloaded upon signing up at:
http://www.investor-edge.com/388-register
Shares in IntelliPharmaCeutics International Inc. recorded a
trading volume of 1.42 million shares, as compared with a three
months average volume of 0.63 million shares. The stock finished
the day at $4.79, up 9.11% after
trading between $4.34 and $4.83.
IntelliPharmaCeutics International Inc.'s shares have surged 11.66%
in the previous three trading sessions, 27.93% in the last one
month, and 29.11% on YTD basis. The company's shares are trading
above their 50-day and 200-day moving averages of $3.95 and $2.69,
respectively. Additionally, shares of the company are trading at a
Relative Strength Index (RSI) of 59.87. Sign up today to read free
research on IPCI at:
http://www.investor-edge.com/388-IPCI-.pdf
Delcath Systems Inc.'s shares recorded a trading volume of 19.28
million shares, as compared with a three months average volume of
4.66 million shares. The stock ended the day at $0.35, up 0.20% and recorded an intraday range of
$0.34 - $0.42. Delcath Systems Inc.'s
shares have gained 13.72% in the previous three trading sessions,
11.91% in the last one month, and 37.53% on YTD basis. The
company's stock is trading above its 50-day moving average. Delcath
Systems Inc.'s 200-day moving average of $0.35 is above the 50-day moving average of
$0.32. Furthermore, the stock is
trading at an RSI of 58.43. Sign up today to read free research on
DCTH at:
http://www.investor-edge.com/388-DCTH-.pdf
Shares in Valeant Pharmaceuticals International Inc. edged 0.28%
lower to finish the day at $140.40.
The stock recorded trading volume of 0.99 million shares as
compared to a three months average volume of 1.60 million shares.
The stock fluctuated between $139.08 and
$141.97 during the session. Valeant Pharmaceuticals
International Inc.'s shares have lost 0.35% in the previous three
trading sessions, and 5.14% in the last one month, while gaining
19.59% on YTD basis. The company's stock is trading above its
50-day and 200-day moving averages of $138.78 and $110.73, respectively. Moreover, the stock is
trading at an RSI of 50.02. Sign up today to read free research on
VRX at:
http://www.investor-edge.com/388-VRX-.pdf
On Thursday, shares in Alkermes PLC gained 1.34%, closing the day
at $47.51. The stock recorded trading
volume of 1.26 million shares as compared to a three months average
volume of 0.99 million shares. The stock fluctuated between
$46.57 and $47.97 during the trading
session. Shares of the company traded at a PE ratio of 174.03.
Alkermes PLC's shares have advanced 3.64% in the previous three
trading sessions and 16.85% on YTD basis, while falling by 10.29%
in the last one month. The company's stock is trading below its
50-day moving average. Alkermes PLC's 50-day moving average of
$48.54 is above the 200-day moving
average of $37.74. Additionally, the
stock is trading at an RSI of 45.16. Sign up today to read free
research on ALKS at:
http://www.investor-edge.com/388-ALKS-.pdf
EDITOR'S NOTES:
1. This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
3. This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at
compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage
on your company? Send us a full investors' package to research [at]
http://www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis.
This document, article or report is prepared and authored by
Investor-edge. An outsourced research services provider represented
by Nidhi Vatsal, CFA, has only reviewed the information provided by
Investor-edge in this article or report according to the Procedures
outlined by Investor-edge. Investor-edge is not entitled to veto or
interfere in the application of such procedures by the outsourced
provider to the articles, documents or reports, as the case may
be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or
otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Investor-edge
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Investor-edge expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Investor-edge does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Investor-Edge